v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 24 Months Ended 30 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Mar. 29, 2026
Mar. 29, 2026
Restructuring Cost and Reserve [Line Items]        
Restructuring charges [1] $ 49 $ 621    
Productivity and Operational Efficiencies [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 6      
Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 31 617    
Realigning Our Cost Base Program [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 5,300   $ 5,300 $ 5,300
Restructuring cost incurred to date 4,300   4,300 4,300
Realigning Our Cost Base Program [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 3,700   3,700 3,700
Restructuring cost incurred to date 3,300   3,300 3,300
Restructuring charges 47 587   2,900
Realigning Our Cost Base Program - Initial Phase [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 4,700   4,700 4,700
Realigning Our Cost Base Program - Initial Phase [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 3,100   3,100 3,100
Realigning Our Cost Base Program - Research and Development [Member] | Biopharma [Member] | Productivity and Operational Efficiencies [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 600   600 600
Manufacturing Optimization Program [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring cost incurred to date 1,100   1,100 1,100
Restructuring charges (22) $ (4) 853  
Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost $ 1,400   $ 1,400 $ 1,400
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).